Episode 116: Should Low-Grade Prostate Cancer Be Considered Cancer?

Jonathan Epstein & Scott Eggener on Healthcare Unfiltered Podcast

Episode 116: Should Low-Grade Prostate Cancer Be Considered Cancer?

Scott Eggener, MD, University of Chicago, and Jonathan Epstein, MD, The Johns Hopkins Medical Institutions, join the show to debate whether Gleason Score 6 prostate cancer should be renamed to non-cancer. The trio hit on what should happen upon diagnosis and Gleason grade 6, which patients should be offered active surveillance, the benefits and risks of not calling this diagnosis “cancer,” how often and how frequently to biopsy, overscreening, and many other discussion points.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 206: Fireside Chat With Joe Mikhael, the CMO of the IMF

Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding

Read More

Episode 205: Multi-Cancer Early Detection (MCED): Now and Later

Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary

Read More